Replimune Group

About Replimune Group

Replimune Group is a pioneering biotechnology company based in the UK, dedicated to developing innovative oncolytic virus therapies for the treatment of cancer. Our mission is to harness the power of the immune system to target and destroy cancer cells while sparing healthy tissue. We believe that our unique approach can significantly improve patient outcomes and quality of life.

At Replimune, we focus on creating a new class of immunotherapies that utilize genetically modified viruses to selectively infect and kill cancer cells. Our lead product candidates are designed to stimulate a robust immune response against tumours, providing a dual mechanism of action that not only targets the cancer directly but also activates the body’s immune system to fight the disease.

Our research and development efforts are driven by a team of experienced scientists and industry professionals who are committed to advancing the field of cancer treatment. We collaborate with leading academic institutions and research organisations to stay at the forefront of scientific innovation.

We are currently conducting clinical trials to evaluate the safety and efficacy of our therapies in various types of cancer, including melanoma and other solid tumours. Our goal is to bring these groundbreaking treatments to market and make a meaningful difference in the lives of patients battling cancer.

As we continue to grow, we remain focused on our core values of integrity, collaboration, and excellence. We are dedicated to fostering a culture of innovation and inclusivity within our organisation, ensuring that every team member contributes to our shared vision of transforming cancer care.

In summary, Replimune Group is at the forefront of cancer therapy innovation, leveraging cutting-edge technology to develop effective treatments that empower patients and enhance their quality of life.